Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma

Inclusion Criteria: * Histologically confirmed, aggressive B-cell NHL at relapse/progression or PR after front line therapy. Aggressive B-cell NHL is heretofore defined by the following list of subtypes (Swerdlow et al 2016): * DLBCL, NOS, * FL grade 3B, * Primary mediastinal large B cell lymphoma (PMBCL), * T cell rich/histiocyte rich large B cell lymphoma (T/HRBCL), * DLBCL associated with chronic inflammation, * Intravascular large B-cell lymphoma, * ALK+ large B-cell lymphoma, * B-cell lymphoma, unclassifiable, (with features intermediate between DLBCL and classical Hodgkin's Lymphoma (HL)), * High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, * High-grade B-cell lymphoma, NOS * HHV8+ DLBCL, NOS * DLBCL transforming from follicular lymphoma * DLBCL transforming from marginal zone lymphoma * DLBCL, leg type * Relapse or progression within 365 days from last dose of anti CD20 antibody and anthracycline containing first line immunochemotherapy or refractory (have not achieved a CR). * Patient is considered eligible for autologous HSCT as per local investigator assessment. Note: Intention to transplant and type of high dose chemotherapy (HDCT) regimen will be documented at the time of study entry * Disease that is both active on PET scan (defined as 5-Deauville scorepoint-scale of 4 or 5) and measurable on CT scan, defined as:: * Nodal lesions \>15 mm in the long axis, regardless of the length of the short axis, and/or …